In patients with advanced nonsmall cell lung cancer resistant to EGFR inhibitors, adding a MET inhibitor to osimertinib was beneficial, but adding a MEK inhibitor was not.
Medscape Medical News
New Approach in Advanced NSCLC: Adding MET Inhibitor Savolitinib
